Digital biosensor for human cerebrospinal fluid detection with single-use sensing strips.

Accurate detection of cerebrospinal fluid (CSF) leakage remains a diagnostic challenge in clinical settings. Traditional methods like enzyme-linked immunosorbent assay and immunofixation electrophoresis are limited to specialized labs, which can delay diagnosis. Beta-2-transferrin (B2T) is a unique biomarker of CSF, but its detection at the point of care is not yet widely established. Prior research has shown that B2T is absent in other bodily fluids, making it a potential diagnostic target. However, no prior work had resolved how to detect B2T rapidly and sensitively outside of reference laboratories. This gap motivated the development of a portable electrochemical sensor. The study aimed to address the need for a faster and more accessible CSF detection method. Establishing a reliable point-of-care test could reduce delays in diagnosis and treatment. The novelty lies in applying electrochemical sensing to detect B2T in real-world clinical scenarios.

The purpose of this study was to develop and validate a single-use electrochemical biosensor for detecting beta-2-transferrin (B2T) in human cerebrospinal fluid (CSF). The sensor is intended for point-of-care use, allowing rapid diagnosis of CSF leakage. The researchers sought to overcome the limitations of current diagnostic methods, which require specialized labs and may delay treatment. The study focused on ensuring the sensor's accuracy across a range of B2T concentrations. The goal was to confirm the sensor's ability to detect B2T at very low levels while maintaining sensitivity. Validation was performed using human samples with known B2T concentrations. The researchers also aimed to test the sensor's reliability when applied to different patient samples. This approach could provide a faster and more accessible alternative to existing methods.

The study employed an electrochemical biosensor designed for point-of-care detection of beta-2-transferrin (B2T). The sensor uses single-use sensing strips to ensure hygiene and accuracy. Serial dilution experiments were conducted to assess the sensor's sensitivity across a range of B2T concentrations. Human CSF samples with known B2T levels were diluted up to 100 times to test the sensor's performance. The researchers compared sensor outputs with expected values to evaluate accuracy. No prior work had tested such dilution ranges in real-world samples using electrochemical methods. The sensor's response was measured in microgram per milliliter units. The study also examined how well the sensor performed across multiple patient samples.

The sensor detected beta-2-transferrin (B2T) at concentrations as low as 7 × 10⁻¹² g/ml in human samples. This level of sensitivity matches or exceeds that of traditional lab-based methods. The sensor maintained accuracy even after diluting samples up to 100 times. Nine different human samples were tested to confirm the sensor's reliability across a range of B2T levels. The results showed consistent detection of B2T across all tested concentrations. The sensor's output correlated well with expected values from serial dilution experiments. No false positives were reported in the tested samples. These findings suggest the sensor could serve as a reliable point-of-care diagnostic tool.

The study demonstrated that the electrochemical biosensor can detect beta-2-transferrin (B2T) at very low concentrations in human cerebrospinal fluid (CSF) samples. The sensor's performance was validated using serial dilution and multiple patient samples. The authors suggest that this method could provide a faster alternative to traditional lab-based tests. The sensor's accuracy and sensitivity make it suitable for point-of-care applications. The results support the potential use of this biosensor in clinical settings where rapid diagnosis is needed. The study does not claim that the sensor is superior to all existing methods but highlights its advantages in speed and accessibility. The findings are specific to the tested B2T concentrations and sample types. The authors propose that further clinical trials may be necessary to confirm broader applicability.